Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IB - Bit confused at message. SequestOx was never approved and don’t think it ever will be. Nasrat sold off opioids and could never get movement on Codeine, which will be sold off for pennies on the dollar once again.
If I remember right some of these products Elite has worked on for years and we’re put on the back burner. Picking them back up shouldn’t be that difficult, but depends where they left off in the process beyond ideation and wishful thinking.
Just another day in selling paradise
If someone likes it on big volume the stock would be green, not red. Ongoing retail selling over and over again.
May have entered, but we don’t have the results. They only take a few weeks to run. I’m hoping we hear of something by end of year that will lead us to a submission in first half of 2022.
No new ANDA news at least a year out. They haven’t published study/bioequivalency results yet let alone filed any submission.
Did I miss something other than a pump attempt?
Could be a run before another round of the short selling begins…
Another day, another seller bailing. Lower lows along with lower highs. Lovely 8 year trend.
Half of NJ under flood watch and throw in tornadoes in the mix. Hope all stay safe.
Did you buy all of those 11 shares?
Extremely liquid stock. Lol
Hope management pats themselves on the back for all the hard work over the past 8 years. They’ve done an amazing job to the tune of ~$4K worth exchanging hands today. Zero interest from any sort of investor.
All depends on pipeline execution. If pipeline executes like Adderall ER, the stock price will stagnate. The only shareholder getting an ROI is the CEO from side deals with Mikah.
Management is positive about rebuilding pipeline, but they are feeling pretty positive about tiny drugs in the current portfolio as well which will do minimal to get this stock moving. Until the company clarifies ANDAs and selects better partners the revenue, stock price and shareholders will continue to feel the pain and be left in the dark.
Correct, but just like any other publicly held company, Elite’s CEO has threatened to dilute for the right opportunity. With an already bloated float that is just starting to break even one would think the company would have hundreds of millions in revenue by this time.
It’s using history as a guide, which isn’t the best as Elite is starting to move in the right direction albeit at the hastening pace of a sleeping sloth. This will be a turnaround story that will take 10-12 years under current management. Not exactly lightning fast, but painfully limping along at the 3rd attempt at a new company strategy.
In the eyes of the realist, the stock has sunk 50% since the CEO came on board many years ago.
Why would this stock deserve a 40-80 forward PE?
Not a chance Elite is going to enter this space. PDE has billions to throw at R&D. Elite has maybe a couple million. Dream away.
A significant number of pharmaceuticals have a presence in New Jersey. It’s like saying Target has a relationship with Best Buy because their headquarters are near each other and in the same industry. Meaningless.
Elite has always provided updates on the outcome of the trials prior to FDA submission or at least when the results are favorable.
Next fiscal update won’t be until mid-November. It is likely that we will receive study/bioequivalency results before then if Elite is focusing on 4 ANDA submissions next year unless they are all back half of the year. These will help us better understand scope and timing of next ANDA submissions.
Is that new term for the “poop touch”?
Down worse after hours. Rev missed their own expectations. Sound familiar? :)
With the exception of LCI’s generic Concerta, which is their biggest growth opportunity. Their CNS revs increased all last year, while at the same time Elite’s revenue decreased. The correlation to LCI’s CNS revenue doesn’t exist anymore because of their laser focus on generic Concerta.
Funny, Elite has said it isn’t pursuing opioids.
FYI - Abusers are a fraction of the market and this simply ignores the bulk of the patients who need opioids for pain management. Those involved in the deceit should be punished, but a tiny little company with no resources to go after wouldn’t be included. That assumption can be found in the fiction section.
The stock is down due to failure to meet Elite’s own communicated expectations for the last 8 years - SequestOx, Sungen, 3-prong strategy, Adderall expectations, generic opioids after spending millions in R&D, etc. The company is moving in the right direction, but ever so slowly. Even a good company, can be a really crappy stock.
Except the only shorts here are those worn under the desk. Rest is just imagination.
Poor stock performance is just the gold standard here.
Why would you think it would have anything to do with Covid? The company has said the focus is on generics with harder barrier to entry, it has said it isn’t approved or have the facilities for vaccine manufacturing. This is a comment that isn’t even a guesstimate based on fact or anything remotely close to it. It is really just a way for the stock to be pumped so am exit can be made.
That’s a big assumption and depends on a myriad of other factors.
Interesting, thanks for sharing. Kind of funny how there’s more near term potential with Phentermine than Adderall and a $1.5B+ market.
Oh, the chart I have been looking at is upside down! Silly me.
Master of deflection without lack of accountability and consistent inability to execute well.
That’s what bagholders say when a stock keeps falling - it’s simply accumulation. :)
Strong hype was based on ART potential, which turned out to be a dud.
Not sure I agree. Elite isn’t close to maximizing usage of facility now. Even if they captured all - the $20M isn’t going to force new expansion and need more space. My guess is they are overestimating again, similar to Adderall expectations. Or the expansion could just be for be for larger office space. :)
Exactly. There is nothing to showcase what we are selling today and in the future that is going to drive stock north. We are waffling until the company is sold.
This isn’t manipulation. This is the fact that management is taking longer to execute. They are delivering sales much lower than expected and previously communicated. The. Company isn’t meeting the hurdle they set for themselves.
Elite is moving forward, but at a snail’s pace. $7M in revenue is not going to move the needle with a billion in O/S to gear up new investor interest.
The stock price doesn’t magically just increase. Why isn’t mgmt going to investor conferences? Why doesn’t the company publicize new initiatives? Because they aren’t worth honking the horn at yet. Perhaps in a couple more years.
Agree 100%. I think we may start to get traction in closer to 18-24 months. Who knows what stock will do during that time, but no pressure to drive it north for sure.
Elite has over promised historically due to many CRLs in past that pushed back timelines time and time again. We simply know of 4 ANDAs next year at some time with approval process starting subsequent year. We still have a year ahead with no new launches.